GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Willow Biosciences Inc (TSX:WLLW) » Definitions » EV-to-EBIT

Willow Biosciences (TSX:WLLW) EV-to-EBIT : -1.31 (As of Jun. 25, 2024)


View and export this data going back to 1983. Start your Free Trial

What is Willow Biosciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Willow Biosciences's Enterprise Value is C$13.75 Mil. Willow Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was C$-10.51 Mil. Therefore, Willow Biosciences's EV-to-EBIT for today is -1.31.

The historical rank and industry rank for Willow Biosciences's EV-to-EBIT or its related term are showing as below:

TSX:WLLW' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.91   Med: -0.67   Max: 1.58
Current: -1.31

During the past 13 years, the highest EV-to-EBIT of Willow Biosciences was 1.58. The lowest was -4.91. And the median was -0.67.

TSX:WLLW's EV-to-EBIT is ranked worse than
100% of 669 companies
in the Drug Manufacturers industry
Industry Median: 16.85 vs TSX:WLLW: -1.31

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Willow Biosciences's Enterprise Value for the quarter that ended in Mar. 2024 was C$13.09 Mil. Willow Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was C$-10.51 Mil. Willow Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -80.32%.


Willow Biosciences EV-to-EBIT Historical Data

The historical data trend for Willow Biosciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Willow Biosciences EV-to-EBIT Chart

Willow Biosciences Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.69 -2.89 -4.30 0.01 -0.89

Willow Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.70 -0.71 -0.89 -1.25

Competitive Comparison of Willow Biosciences's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Willow Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Willow Biosciences's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Willow Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Willow Biosciences's EV-to-EBIT falls into.



Willow Biosciences EV-to-EBIT Calculation

Willow Biosciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=13.750/-10.512
=-1.31

Willow Biosciences's current Enterprise Value is C$13.75 Mil.
Willow Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-10.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Willow Biosciences  (TSX:WLLW) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Willow Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-10.512/13.0881
=-80.32 %

Willow Biosciences's Enterprise Value for the quarter that ended in Mar. 2024 was C$13.09 Mil.
Willow Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-10.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Willow Biosciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Willow Biosciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Willow Biosciences (TSX:WLLW) Business Description

Traded in Other Exchanges
Address
202, 1201 5th Street SW, Calgary, AB, CAN, T2R 0Y6
Willow Biosciences Inc is a Canadian biotechnology company. It has only one reportable segment engaged in developing and producing high-purity, plant-derived ingredients for consumer care, food and beverage, and pharmaceutical products. Geographically, it derives a majority of its revenue from Canada.
Executives
Patricia Ranija Choudhary Director

Willow Biosciences (TSX:WLLW) Headlines

No Headlines